76568-02-0|Flosequinan|4(1H)-Quinolinone, 7-fluoro-1-methyl-3-(methylsulfinyl)-|-范德生物科技公司

Flosequinan

NMR下载 COA and HPLC MSDS下载
names：
4(1H)-Quinolinone, 7-fluoro-1-methyl-3-(methylsulfinyl)-
CAS号：
76568-02-0
MDL Number：
MF(分子式)： C11H10FNO2S MW(分子量)： 239.2644
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
FMK15337-100mg	100mg	>98%	¥ 0.00	¥ 0.00		Get quote	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Flosequinan
英文别名	Flosequinan
CAS号	76568-02-0
Inchi	InChI=1S/C11H10FNO2S/c1-13-6-10(16(2)15)11(14)8-4-3-7(12)5-9(8)13/h3-6H,1-2H3
InchiKey	UYGONJYYUKVHDD-UHFFFAOYSA-N
分子式 Formula	C11H10FNO2S
分子量 Molecular Weight	239.2644
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Flosequinan(CAS:76568-02-0):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Flosequinan is an arteriovenous vasodilator that has shown to be effective for the treatment of acute heart failure.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Yano M, Kohno M, Yamamoto T, Hisaoka T, Tanigawa T, Ono K, Lee B, Konishi M, Matsuzaki M. Effects of balanced vasodilator, flosequinan, on aortic impedance in failing heart. J Cardiovasc Pharmacol. 1998 Sep;32(3):466-70. PubMed PMID: 9733361.

[2]Cavero PG, De Marco T, Kwasman M, Lau D, Liu M, Chatterjee K. Flosequinan, a new vasodilator: systemic and coronary hemodynamics and neuroendocrine effects in congestive heart failure. J Am Coll Cardiol. 1992 Dec;20(7):1542-8. PubMed PMID: 1452928.

[3] Kashiyama E, Yokoi T, Todaka T, Odomi M, Kamataki T. Chiral inversion of drug: role of intestinal bacteria in the stereoselective sulphoxide reduction of flosequinan. Biochem Pharmacol. 1994 Jul 19;48(2):237-43. PubMed PMID: 8053920.

[4] Sim MF, Yates DB, Parkinson R, Cooling MJ. Cardiovascular effects of the novel arteriovenous dilator agent, flosequinan in conscious dogs and cats. Br J Pharmacol. 1988 Jun;94(2):371-80. PubMed PMID: 3293682; PubMed Central PMCID: PMC1854003.

[5] Kessler PD, Packer M, Medina N, Yushak M. Cumulative hemodynamic response to short-term treatment with flosequinan (BTS 49465), a new direct-acting vasodilator drug, in severe chronic congestive heart failure. J Cardiovasc Pharmacol. 1988 Jul;12(1):6-11. PubMed PMID: 2459536.

6: Miao L, Perreault CL, Travers KE, Morgan JP. Mechanisms of positive inotropic action of flosequinan, hydralazine, and milrinone on mammalian myocardium. Eur J Pharmacol. 1997 Feb 26;321(2):201-8. PubMed PMID: 9063689.7: Silke B, Tennet H, Fischer-Hansen J, Keller N, Heikkila J, Salminen K. A double-blind, parallel-group comparison of flosequinan and enalapril in the treatment of chronic heart failure. Eur Heart J. 1992 Aug;13(8):1092-100. PubMed PMID: 1505560.8: Kashiyama E, Yokoi T, Odomi M, Kamataki T. Stereoselective S-oxidation and reduction of flosequinan in rat. Xenobiotica. 1999 Aug;29(8):815-26. PubMed PMID: 10553722.9: Elborn JS, Stanford CF, Nicholls DP. Effect of flosequinan on exercise capacity and symptoms in severe heart failure. Br Heart J. 1989 Apr;61(4):331-5. PubMed PMID: 2653391; PubMed Central PMCID: PMC1216672.10: Elborn JS, Riley M, Stanford CF, Nicholls DP. The effects of flosequinan on submaximal exercise in patients with chronic cardiac failure. Br J Clin Pharmacol. 1990 May;29(5):519-24. PubMed PMID: 2112405; PubMed Central PMCID: PMC1380150.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开